ETF Holdings Breakdown of SRPT

News associated with SRPT

Stifel Financial Corp Sells 27,138 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Stifel Financial Corp cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 72.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,069 shares of the biotechnology company’s stock after selling 27,138 shares during the quarter. Stifel Financial Corp’s […] - 2025-05-09 08:23:04

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $157.95 Consensus PT from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-three research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has assigned a strong buy […] - 2025-05-09 07:07:04

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 19% Following Weak Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) was down 19% during mid-day trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $56.36 and last traded at $51.54. Approximately 2,597,711 shares traded hands during trading, an increase of 80% from the average daily volume of 1,442,184 shares. The […] - 2025-05-08 06:14:43

Dimensional Fund Advisors LP Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dimensional Fund Advisors LP grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 10.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 310,810 shares of the biotechnology company’s stock after acquiring an additional 30,615 shares during the period. Dimensional Fund Advisors LP’s holdings in Sarepta Therapeutics were worth $37,791,000 at […] - 2025-05-05 08:20:50

Mariner LLC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mariner LLC boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 14.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,042 shares of the biotechnology company’s stock after buying an additional 1,035 shares during the period. Mariner LLC’s holdings in Sarepta Therapeutics were worth $978,000 at the end of […] - 2025-04-28 07:59:00

Piper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target dropped by investment analysts at Piper Sandler from $182.00 to $110.00 in a report issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price target suggests a potential upside of 85.47% from the stock’s previous […] - 2025-04-23 05:10:54

Sterling Capital Management LLC Trims Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sterling Capital Management LLC lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 11.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,464 shares of the biotechnology company’s stock after selling 190 shares during the period. Sterling Capital Management LLC’s holdings […] - 2025-04-22 08:13:08

Sarepta Therapeutics (NASDAQ:SRPT) Given New $182.00 Price Target at Morgan Stanley

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective decreased by Morgan Stanley from $196.00 to $182.00 in a research note published on Friday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other research analysts have also recently weighed in on SRPT. Wells Fargo & Company initiated […] - 2025-04-14 05:44:50

Schroder Investment Management Group Purchases 2,320 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Schroder Investment Management Group increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 72.4% during the fourth quarter, Holdings Channel reports. The fund owned 5,523 shares of the biotechnology company’s stock after purchasing an additional 2,320 shares during the period. Schroder Investment Management Group’s holdings in Sarepta Therapeutics were worth […] - 2025-04-08 08:16:56

LPL Financial LLC Has $6.50 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares of the biotechnology company’s stock after purchasing an additional 5,895 shares during the quarter. LPL Financial LLC’s holdings in Sarepta Therapeutics were worth $6,497,000 at the […] - 2025-04-07 07:34:54

Mitsubishi UFJ Asset Management Co. Ltd. Has $307,000 Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 11.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,429 shares of the biotechnology company’s stock after buying an additional 243 shares during the quarter. […] - 2025-04-04 08:55:06

Commonwealth Equity Services LLC Has $773,000 Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Commonwealth Equity Services LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 22.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,357 shares of the biotechnology company’s stock after purchasing an additional 1,151 shares during the period. Commonwealth Equity Services LLC’s holdings in Sarepta Therapeutics were […] - 2025-04-03 07:54:48

Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to “Sector Perform” at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $87.00 target price on the biotechnology company’s stock, down from their previous target price […] - 2025-04-02 06:00:47

Corient Private Wealth LLC Invests $786,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Corient Private Wealth LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,468 shares of the biotechnology company’s stock, valued at approximately $786,000. Several other institutional investors and […] - 2025-03-28 08:16:56

HighTower Advisors LLC Sells 2,559 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

HighTower Advisors LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 6.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,774 shares of the biotechnology company’s stock after selling 2,559 shares during the period. HighTower Advisors LLC’s holdings in Sarepta […] - 2025-03-20 09:18:48

Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports. They currently have a $202.00 price target on the biotechnology company’s stock. Needham & Company LLC’s target price points to a potential upside of 152.59% from […] - 2025-03-20 06:44:48

Sarepta Therapeutics (NASDAQ:SRPT) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $163.00 price objective on the biotechnology company’s stock. A number of other research analysts have also commented on the company. Scotiabank began coverage on Sarepta […] - 2025-03-19 08:36:46

Proficio Capital Partners LLC Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Proficio Capital Partners LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 31,492 shares of the biotechnology company’s stock, valued at approximately $3,829,000. Several other institutional investors and hedge funds have also […] - 2025-03-18 08:11:10

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Moderate Buy” by Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have issued a buy recommendation and one […] - 2025-03-17 06:12:55

Charles Schwab Investment Management Inc. Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Charles Schwab Investment Management Inc. boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 623,749 shares of the biotechnology company’s stock after acquiring an additional 12,000 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sarepta Therapeutics were […] - 2025-03-11 09:39:03

Oppenheimer Asset Management Inc. Decreases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Oppenheimer Asset Management Inc. decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 8.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,079 shares of the biotechnology company’s stock after selling 378 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $496,000 at […] - 2025-03-06 11:01:21

Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low After Analyst Downgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday after Royal Bank of Canada lowered their price target on the stock from $165.00 to $161.00. Royal Bank of Canada currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $101.00 […] - 2025-02-28 09:30:56

CIBC Asset Management Inc Has $347,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

CIBC Asset Management Inc raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,851 shares of the biotechnology company’s stock after acquiring an additional 139 shares during the quarter. CIBC […] - 2025-02-24 10:04:53

New York State Teachers Retirement System Reduces Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

New York State Teachers Retirement System lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.7% during the 4th quarter, Holdings Channel reports. The firm owned 76,849 shares of the biotechnology company’s stock after selling 1,326 shares during the quarter. New York State Teachers Retirement System’s holdings in Sarepta Therapeutics […] - 2025-02-19 10:44:50

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 267,933 shares of the biotechnology company’s stock after selling 2,939 shares during the period. Rhumbline Advisers’ […] - 2025-02-19 09:18:32

State of Alaska Department of Revenue Sells 145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 10,890 shares of the biotechnology company’s stock after selling 145 shares during the period. State of Alaska Department of Revenue’s holdings in Sarepta Therapeutics were worth […] - 2025-02-13 09:38:55

Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The firm set a “hold” rating and a $136.00 price target on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […] - 2025-02-13 08:46:49

Blue Trust Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Blue Trust Inc. grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 56.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 891 shares of the biotechnology company’s stock after acquiring an additional 323 shares during the quarter. Blue Trust Inc.’s holdings in Sarepta Therapeutics were worth $111,000 at the end of […] - 2025-02-07 08:32:56

SRPT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	55,983	USD 2,044,499
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	33,427	USD 1,220,754
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	121,430	USD 4,434,624
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	46,201	USD 1,687,261
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	46,201	USD 1,687,261 -0.5%
2025-05-08	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	939	USD 34,292 -0.5%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	591	USD 21,583
Total =		304,772	USD 11,130,274

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer